하이텍팜
Financials
Valuation Metrics
하이텍팜's Market Cap is ₩943B. At end of 2025 it was ₩1278B. Ranked #1258 of 2,405 in KR market (top 52%), #683 of 1,627 on KOSDAQ (top 42%), #141 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 94.32B KRW | KR#1,258/2,405 Sec#141/231 |
| Revenue | 69.41B KRW | KR#1,621/2,405 Sec#106/231 |
| Net Income | 11.93B KRW | KR#903/2,405 Sec#59/231 |
| Total Assets | 143.70B KRW | KR#1,538/2,405 Sec#116/231 |
| Net Assets | 130.67B KRW | KR#1,227/2,405 Sec#94/231 |
| Employees | 125 | KR#1,464/2,405 Sec#117/231 |
| Value | ||
| P/E | 7.91x | KR#702/2,405 Sec#31/231 |
| P/B | 0.72x | KR#1,220/2,405 Sec#70/231 |
| PEG | 0.61x | KR#721/2,405 Sec#46/231 |
| P/S | 1.36x | KR#1,638/2,405 Sec#95/231 |
| EV/EBITDA | 6.62x | KR#397/2,405 Sec#14/231 |
| FCF Yield | 16.01% | KR#446/2,405 Sec#11/231 |
| Profitability | ||
| ROE | 9.13% | KR#688/2,405 Sec#47/231 |
| ROA | 8.30% | KR#416/2,405 Sec#31/231 |
| Op. Margin | 17.68% | KR#210/2,405 Sec#20/231 |
| Revenue Growth | -7.02% | KR#1,839/2,405 Sec#174/231 |
| Earnings Growth | 12.91% | KR#738/2,405 Sec#49/231 |
| Financial Health | ||
| Debt Ratio | 9.97% | KR#140/2,405 Sec#29/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 15.10B KRW | KR#597/2,405 Sec#31/231 |
| Cash | 13.08B KRW | KR#1,529/2,405 Sec#124/231 |
| Net Debt/EBITDA | -1.07x | KR#372/2,405 Sec#19/231 |
| Dividend | ||
| Div. Yield | 1.69% | KR#990/2,405 Sec#52/231 |
| Div. Growth | 50.00% | KR#227/2,405 Sec#9/231 |
| Performance | ||
| 1Y Return | -29.44% | KR#1,474/2,405 Sec#119/231 |
| 1M Return | -12.70% | KR#1,393/2,405 Sec#137/231 |
| From 52W High | -64.52% | KR#1,857/2,405 Sec#154/231 |
| 1Y MDD | -65.40% | KR#1,738/2,405 Sec#149/231 |
| Trading | ||
| Volume | 6,743 shares | KR#2,005/2,405 Sec#201/231 |
| Trading Value | 58.8M KRW | KR#1,649/2,405 Sec#173/231 |
| Foreign Own. | 46.42% | KR#44/2,405 Sec#3/231 |
| Per Share | ||
| EPS | 1,122 KRW | KR#681/2,405 Sec#44/231 |
| BPS | 12,289 KRW | KR#838/2,405 Sec#59/231 |
Company Info
Hitech Pharm, established in 1998 and headquartered in Chungju, Chungcheongbuk-do, is a specialized enterprise for antibiotic raw pharmaceutical ingredients, listed on KOSDAQ in 2010. It primarily produces Carbapenem-class antibiotics, with main products Imipenem and Ertapenem, which are high-priced due to their high antibacterial activity, and largely exported to Europe and Asia. The company possesses Carbapenem-class antibiotic technology achieving higher yields and lower impurities than competitors, fostering its growth in the global market via next-generation production plants.